Table 1 Relationship between SSEA-4 expression and the clinicopathological features of 99 patients with prostate cancer tissue.
Factor | Category | Total no. of patients | SSEA-4 negative (n = 22) | SSEA-4 positive (n = 77) | P |
|---|---|---|---|---|---|
Age (years) | >65 | 43 | 9(40.9) | 34(44.1) | 0.786 |
≤65 | 56 | 13(59.1) | 43(55.9) | ||
Pathological stage (pT) | pT2 – pT3a | 43 | 5(22.7) | 38(49.4) | 0.026* |
pT3b | 56 | 17(77.3) | 39(50.6) | ||
Lymph node status | Positive | 58 | 18(81.8) | 40(51.9) | 0.012* |
Negative | 41 | 4(18.2) | 37(48.1) | ||
Tumour margins | Positive | 21 | 8(36.6) | 13(16.9) | 0.049* |
Negative | 78 | 14(63.4) | 64(83.1) | ||
Capsular invasion | No invasion | 66 | 12(54.5) | 54(70.1) | 0.171 |
Invasion | 33 | 10(45.5) | 23(29.9) | ||
PSA concentration (ng/mL) before surgery | Median (range) | 17.40(1.22–105) | 21.59(3.38–91.45) | <0.001** | |
Mean | 21.22 | 25.94 | |||
Gleason score | Gleason≤6 | 27 | 11(50.0) | 16 (20.8) | 0.007* |
Gleason≥7 | 72 | 11(50.0) | 61(79.2) | ||
Biochemical recurrence | Yes (≥0.2 ng/mL) | 76 | 13(59.1) | 63(81.8) | 0.026* |
No (<0.2 ng/mL) | 23 | 9(40.9) | 14(18.2) |
